In this issue of the JCI, Schaub et al. describe changes in single-cell transcriptomics among young people with type 2 diabetes who were SGLT2 inhibitor users compared with nonusers and healthy controls (18). Here, SLC5A2 is linked to type 2 diabetes mellitus.